Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786990 · ClinicalTrials.gov registry record · Phase 4
Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
A Phase 4 study of Attention Deficit/Hyperactivity Disorder (ADHD), sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
- 17
- Study locations
NCT04786990 is a Phase 4 study of Attention Deficit/Hyperactivity Disorder (ADHD) that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 96 participants. The trial reports 17 study locations across 14 states.
The verdict
NCT04786990, a Phase 4 study of Attention Deficit/Hyperactivity Disorder (ADHD), has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
- 17
- Study locations
Study Summary
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
Conditions Studied
Interventions
- DRUG SPN-812
Study Locations (17)
Florida
- Miami Clinical Research - Miami
- APG Research, LLC - Orlando
Idaho
- Elite Clinical Trials - Blackfoot
- Elite Clinical Trials - Rexburg
Texas
- Gadolin Research, LLC - Beaumont
- Family Psychiatry of The Woodlands - The Woodlands
Arkansas
- Preferred Research Partners, Inc. - Little Rock
California
- NRC Research Institute - Orange
Indiana
- Qualmedica Research, LLC - Evansville
Kansas
- Psychiatric Associates Purehealth Medical Center - Overland Park
Missouri
- Midwest Research Group - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-07-27 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786990
The ClinicalTrials.gov registry entry for NCT04786990 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder (ADHD) appearing as the primary indexed condition, and to 1 intervention - of which SPN-812 is the first listed.
NCT04786990 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Florida, Idaho, Texas.
Frequently Asked Questions
What is clinical trial NCT04786990 about?
NCT04786990 is a clinical study titled "Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD". This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
What is the current status of trial NCT04786990?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2021-07-27. Estimated completion is 2023-07-26.
What conditions does trial NCT04786990 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder (ADHD).
What interventions are being tested in trial NCT04786990?
The interventions under investigation include: SPN-812 (DRUG).
Who is sponsoring clinical trial NCT04786990?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04786990 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder (ADHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
COMPLETED · Phase 4
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.